Reasonable. No options here, either. I really don’t see it either. Just thinking out loud. It would be an interesting way to flesh out the shorts, if. And the covering would be interesting to watch, from an evidentiary point of view, if.
I think short covering is likely, in any case, from those short. The cost of borrowing to short, legally, is gonna get tough. Hard to borrow and expensive. And unsustainable, against likely coming good news. No more Naked Shorting. Too many eyes. No more spoofing. Too many eyes. Their problem is the naked shares they haven’t covered, if.
Seems like many find the idea of hedge funds manipulating a little biotech working on a cancer breakthrough unconscionable. Seems like that had been going on here. So, it wouldn’t take much to cause a squeeze, if.
Anyway. Just thinking out loud.